Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Patient Reported Outcomes Of Urinary Incontinence Rates Using Viable Cryopreserved Umbilical Tissue Over Neurovascular Bundles During Robotic Assisted Radical Prostatectomy, Samantha Kraemer, Mit Shah, Chirag Dave, Ji Qi, Fionna Sun, Sugandh Shetty, Brian Seifman, Jason Hafron
Patient Reported Outcomes Of Urinary Incontinence Rates Using Viable Cryopreserved Umbilical Tissue Over Neurovascular Bundles During Robotic Assisted Radical Prostatectomy, Samantha Kraemer, Mit Shah, Chirag Dave, Ji Qi, Fionna Sun, Sugandh Shetty, Brian Seifman, Jason Hafron
Conference Presentation Abstracts
Introduction: Incontinence remains a side effect from robotic assisted radical prostatectomy (RAP) for prostate cancer despite nerve sparing (NS) techniques. Use of growth factors and anti-inflammatory substances over neurovascular bundles is an emerging technique to enhance recovery of continence and potency. Viable cryopreserved umbilical tissue (vCUT) is FDA approved for homologous use in surgery. The objective is to determine if vCUT use in NS-RAP accelerates return to continence. Methods: Retrospective review of 176 patients who underwent NS-RAPs from October 2015 through July 2020 were identified through the Michigan Urological Surgery Improvement Collaborative (MUSIC). Return to social urinary continence (0-1 pads …
Two-Year Outcomes Of The Artisan-Snm Study For The Treatment Of Urinary Urgency Incontinence With The Axonics Rechargeable Sacral Neuromodulation System, Andrea Pezzella, Rebecca Mccrery, Felicia Lane, Kevin Benson, Chris Taylor, Kenneth M. Peters
Two-Year Outcomes Of The Artisan-Snm Study For The Treatment Of Urinary Urgency Incontinence With The Axonics Rechargeable Sacral Neuromodulation System, Andrea Pezzella, Rebecca Mccrery, Felicia Lane, Kevin Benson, Chris Taylor, Kenneth M. Peters
Conference Presentation Abstracts
Introduction: Sacral neuromodulation is a guideline-recommended therapy for treatment of urinary urgency incontinence (UUI) patients [1]. The Axonics® System is the first FDA-approved rechargeable SNM system that is qualified to delivery therapy for at least 15 years. The ARTISAN-SNM study is a prospective, pivotal study, designed to evaluate the safety and effectiveness of the Axonics System for UUI treatment. Clinical outcomes at 2 years are presented. Methods: 129 UUI participants across 19 centers in the US and Europe were implanted with the Axonics System in a single, non-staged procedure. Clinical outcomes were reported from 3-day bladder diaries, a validated quality …